GlassScriptPhysician profile
Ashraf F Henry
NPI 1033147400
$13,204.40
in general payments reported to CMS, 2019-2025
62 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 85% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $982 · 2021: $1,455 · 2022: $1,946 · 2023: $2,472 · 2024: $2,554 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,380.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,464.48 | 2019-2025 | Xtampza, Belbuca |
| Nevro Corp. | $1,147.38 | 2019-2024 | Senza |
| Abbvie INC. | $1,109.17 | 2022-2025 | |
| Sk Life Science, INC. | $885.08 | 2020-2025 | |
| Abbott Laboratories | $855.03 | 2019-2025 | Eterna, Octrode, Penta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $827.90 | 2020-2025 | Relistor |
| Jazz Pharmaceuticals INC. | $679.66 | 2021-2025 | |
| Ucb, INC. | $580.24 | 2021-2025 | Nayzilam, Fintepla, Briviact |
| Scilex Pharmaceuticals INC. | $473.79 | 2019-2025 | Ztlido |
| Averitas Pharma INC. | $433.40 | 2023-2025 | Qutenza |
| Globus Medical, INC. | $423.91 | 2025 | Senza, Vyrsa V1, Omnia |
| Teva Pharmaceuticals USA, INC. | $281.22 | 2019-2024 | Austedo Xr, Ajovy |
| Mdd US Operations, LLC | $266.70 | 2019-2020 | |
| Lundbeck LLC | $220.42 | 2022-2025 | Vyepti, Rexulti |
| Sentynl Therapeutics, INC. | $203.28 | 2019 |
Show all 61 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$491,652.62 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.